Real World Experience of Chronic Hepatitis C Retreatment with Genotype Specific Regimens in Nonresponders to Previous Interferon-Free Therapy

Table 1

Characteristics of nonresponders to interferon-free therapy retreated with genotype specific DAA regimens, compared to the whole population of patients included in the EpiTer-2 database.

Parameter	Studied population
	n=31
females/males, n (%)	16/15 (52%/48%)
Age [years], mean ± SD; min-max	54 ± 11; 23-77
HCV genotype, n (%)
1b	23 (74%)
3	3 (10%)
4	5 (16%)
Fibrosis, n (%)
F0	1 (3%)
F1	3 (10%)
F2	3 (10%)
F3	2 (6%)
F4	22 (71%)
Primary regimen, on schedule/discontinued, n (%)	19/12 (61%/39%)
OBV/PTV/r+DSV ± RBV, on schedule	4 (13%)
OBV/PTV/r+DSV ± RBV, discontinued	11 (35%)
LDV/SOF ± RBV, on schedule	7 (23%)
LDV/SOF ± RBV, discontinued	0
ASV+DCV, on schedule	3 (10%)
ASV+DCV, discontinued	1 (3%)
SOF+RBV, on schedule	3 (10%)
SOF+RBV, discontinued	0
Other SOF based†, on schedule	2 (6%)
Other SOF based†, discontinued	0
History of primary regimen failure, n (%)
Discontinued due to adverse events	11 (35%)
Relapse	10 (32%)
Non-response	9 (29%)
Other‡	1 (3%)
Period between primary and rescue therapy [months], mean ± SD; min-max	9.0 ± 5.0; 0-18

†SOF+SMV+RBV and SOF+DCV+RBV.
‡improper primary regimen discontinued after 4 weeks.
DAA: direct acting antivirals; SD: standard deviation; HCV: hepatitis C virus; F: fibrosis; OBV: ombitasvir; PTV: paritaprevir; DSV: dasabuvir; RBV: ribavirin; LDV: ledipasvir; SOF: sofosbuvir; ASV: asunaprevir; DCV: daclatasvir; SMV: simeprevir.